三阴性乳腺癌的治疗进展

IF 0.5 4区医学 Q4 OBSTETRICS & GYNECOLOGY

European journal of gynaecological oncology Pub Date : 2022-04-15 DOI:10.31083/j.ejgo4302040

S. Krämer, C. Rogmans, Dilek Saylan, D. Friedrich, C. Kraft, G. Rogmans, M. Wirtz, M. Friedrich

{"title":"三阴性乳腺癌的治疗进展","authors":"S. Krämer, C. Rogmans, Dilek Saylan, D. Friedrich, C. Kraft, G. Rogmans, M. Wirtz, M. Friedrich","doi":"10.31083/j.ejgo4302040","DOIUrl":null,"url":null,"abstract":"Triple-negative breast cancer (TNBC) lacks expression of the three biomarkers (the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) protein) and are typically higher grade. While the triple-negative clinical phenotype is heterogeneous, the basal-like molecular subtype comprises a large proportion, particularly for breast cancer susceptibility gene 1 ( BRCA1 )-associated breast cancer. New treatment options are checkpoint inhibitors like inhibition of PD-L1 pathway with pembrolizumab and atezolizumab, parp-inhibition with olaparib or talozoparib and treatment with the an antibody drug conjugate sacituzumab-govitecan.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2022-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Treatment Progress in Triple Negative Breast Cancer\",\"authors\":\"S. Krämer, C. Rogmans, Dilek Saylan, D. Friedrich, C. Kraft, G. Rogmans, M. Wirtz, M. Friedrich\",\"doi\":\"10.31083/j.ejgo4302040\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Triple-negative breast cancer (TNBC) lacks expression of the three biomarkers (the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) protein) and are typically higher grade. While the triple-negative clinical phenotype is heterogeneous, the basal-like molecular subtype comprises a large proportion, particularly for breast cancer susceptibility gene 1 ( BRCA1 )-associated breast cancer. New treatment options are checkpoint inhibitors like inhibition of PD-L1 pathway with pembrolizumab and atezolizumab, parp-inhibition with olaparib or talozoparib and treatment with the an antibody drug conjugate sacituzumab-govitecan.\",\"PeriodicalId\":11903,\"journal\":{\"name\":\"European journal of gynaecological oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2022-04-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European journal of gynaecological oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.31083/j.ejgo4302040\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European journal of gynaecological oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/j.ejgo4302040","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 2

摘要

三阴性乳腺癌(TNBC)缺乏三种生物标志物(雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2 (HER2)蛋白)的表达，通常级别较高。虽然临床三阴性表型具有异质性，但基底样分子亚型占很大比例，尤其是乳腺癌易感基因1 (BRCA1)相关乳腺癌。新的治疗选择是检查点抑制剂，如pembrolizumab和atezolizumab抑制PD-L1通路，olaparib或talozoparib抑制parp，以及抗体药物偶联sacituzumab-govitecan治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Treatment Progress in Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) lacks expression of the three biomarkers (the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) protein) and are typically higher grade. While the triple-negative clinical phenotype is heterogeneous, the basal-like molecular subtype comprises a large proportion, particularly for breast cancer susceptibility gene 1 ( BRCA1 )-associated breast cancer. New treatment options are checkpoint inhibitors like inhibition of PD-L1 pathway with pembrolizumab and atezolizumab, parp-inhibition with olaparib or talozoparib and treatment with the an antibody drug conjugate sacituzumab-govitecan.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European journal of gynaecological oncology 医学-妇产科学

自引率

25.00%

发文量

审稿时长

1 months

期刊介绍： EJGO is dedicated to publishing editorial articles in the Distinguished Expert Series and original research papers, case reports, letters to the Editor, book reviews, and newsletters. The Journal was founded in 1980 the second gynaecologic oncology hyperspecialization Journal in the world. Its aim is the diffusion of scientific, clinical and practical progress, and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists, and so on.